GlassScriptPhysician profile
Cheri Michelle Frederick
NPI 1548868268
$6,958.51
in general payments reported to CMS, 2019-2025
24 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,454 · 2022: $1,658 · 2023: $1,113 · 2024: $1,515 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,820 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.54 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $633.16 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $589.49 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $583.29 | 2021-2025 | |
| Corium, LLC | $574.37 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $563.57 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $514.75 | 2021-2025 | Fanapt |
| Alkermes, INC. | $514.68 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $418.96 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $414.33 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $389.41 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $264.55 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $255.75 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.39 | 2021-2024 | Caplyta |
| Indivior INC. | $219.13 | 2022-2025 | Sublocade, Perseris |
| Janssen Pharmaceuticals, INC | $214.67 | 2021-2025 | Spravato, Invega Sustenna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $142.93 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $117.47 | 2024-2025 | Cobenfy |
| Braeburn INC. | $92.78 | 2023-2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $63.09 | 2025 | Jornay Pm |
| Biogen, INC. | $52.25 | 2025 | Zurzuvae |
| Tris Pharma INC | $51.39 | 2023 | Dyanavel Xr |
| Uswm, LLC | $23.13 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.23 | 2025 | |
| Noven Therapeutics, LLC | $16.74 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.